News

Drugs “refund” scheme proposed for England and Wales

BMJ 2007; 334 doi: https://doi.org/10.1136/bmj.39238.353657.DB (Published 07 June 2007) Cite this as: BMJ 2007;334:1181
  1. Susan Mayor
  1. London

    The drugs advisory body for England and Wales has recommended a “refund” scheme in which the manufacturer of bortezomib (Velcade) would reimburse the NHS for the cost of the drug in patients who do not respond to treatment.

    The refund scheme, proposed by the National Institute for Health and Clinical Excellence (NICE), could signal a way for the NHS to cope with funding the rapidly growing range of new and expensive drugs. It was suggested by the company making bortezomib, Janssen-Cilag, as part of its appeal against NICE's previous recommendation that the drug was not cost effective.

    NICE's independent advisory committee agreed and recommended in draft guidance published this week that all suitable patients with progressive multiple myeloma should be offered bortezomib. Patients who show a full or partial response should continue treatment, …

    View Full Text

    Sign in

    Log in through your institution

    Free trial

    Register for a free trial to thebmj.com to receive unlimited access to all content on thebmj.com for 14 days.
    Sign up for a free trial

    Subscribe